Noble G R, Kaye H S, Yarbrough W B, Fiedler B K, Reed C J, Felker M B, Kendal A P, Dowdle W R
J Infect Dis. 1977 Dec;136 Suppl:S429-34. doi: 10.1093/infdis/136.supplement_3.s429.
Titers of hemagglutination-inhibiting (HAI) antibody were determined for all sera obtained from participants in the 1976 Influenza Vaccine Test Program. At least eight control sera were included in each test during the vaccine trial period for the purpose of monitoring HAI test reproducibility. Estimates of day-to-day reproducibility were defined as the percentages of duplicate aliquots of the same sera, tested on two separate days, having HAI antibody titers that did not differ by more than one twofold dilution. These reproducibility estimates ranged from 89% to 97% with influenza A/New Jersey/76 and A/Mayo Clinic/74 antigens. In contrast, within-day reproducibility estimates obtained from all sets of control sera ranged from 96% to 98%. Estimates of day-to-day test reproducibility obtained with selected sera taken after vaccination that were titrated on two differen days ranged from 90% to 98%. Geometric mean titers of these sera tested weeks or months apart differed on some occasions during the test period.
对1976年流感疫苗测试项目参与者提供的所有血清进行了血凝抑制(HAI)抗体效价测定。在疫苗试验期间,每次检测至少包含8份对照血清,以监测HAI检测的重复性。日常重复性估计值定义为在两个不同日期检测的同一血清的重复样本中,HAI抗体效价相差不超过一倍稀释度的百分比。使用甲型流感/新泽西/76和甲型流感/梅奥诊所/74抗原时,这些重复性估计值在89%至97%之间。相比之下,从所有对照血清组获得的日内重复性估计值在96%至98%之间。对接种疫苗后采集的选定血清在两个不同日期进行滴定,得到的日常检测重复性估计值在90%至98%之间。在测试期间的某些情况下,相隔数周或数月检测的这些血清的几何平均效价有所不同。